
IDEAYA Biosciences, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
IDEAYA Biosciences is a clinical-stage oncology company developing targeted therapeutics, including synthetic lethality-based drug candidates such as darovasertib, aimed at genetically defined patient populations with cancers like uveal melanoma.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Hata Yujiro SPresident and CEO | Sell | $955K | 25,538at $37.39 | Oct 6, 2026 |
| Hata Yujiro SPresident and CEO | Sell | $31K | 800at $38.26 | Oct 6, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable IDYA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.